Skip to main content
Premium Trial:

Request an Annual Quote

Bor-Iuan Jan, Fluidigm

Premium
Bor-Iuan Jan of Pingtung, Taiwan, has received US Patent No. 7,118,908, “On-spot selectively activated hydrophobic slide and preparation thereof.” The patent claims a selectively activated hydrophobic slide or microarray coated with a hydrophobic copolymer. According to the patent’s abstract, the polymer is prepared by the blending, grafting or co-polymerization of a hydrophobic material and a compound bearing a functional group protected by a protecting group, where the functional group is imide or cyclic amide, and the protecting group is a photo acid group such as a tosyloxy group. The hydrophobic copolymer is then formed, coated on a substrate, and then subjected to selective photolithographical activation so that the slide will have functional active copolymer spots separated by inactive copolymers. The resulting slide is suitable for the preparation of arrays, the patent states.
 

 

Fluidigm of South San Francisco, Calif., has received US Patent No. 7,118,910, ”Microfluidic device and methods of using same.” The patent claims a variety of elastomeric-based microfluidic devices and methods for using and manufacturing such devices. Some of the devices have arrays of reaction sites to facilitate high-throughput analyses, according to the patent’s abstract. Some devices also include reaction sites located at the end of blind channels at which reagents have been previously deposited during manufacture. The reagents become suspended once sample is introduced into the reaction site. The devices can be utilized with a variety of heating devices and thus can be used in a variety of analyses requiring temperature control, including nucleic acid amplification reactions, genotyping, and gene expression analyses.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.